14.89USD-6.23%Mkt Cap: 78.89M USDP/E: —Last update: 2026-05-26
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candida…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap78.89M USD
Enterprise Value34.84M USD
Revenue (TTM)858.00K USD
Gross Profit-17.54M USD
Net Income (TTM)-8.98M USD
Revenue/Share0.1520 USD
Last Price14.89 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.85
PEG—
EV/EBITDA-1.15
EV/Revenue40.61
P/S94.97
P/B1.62
EPS (TTM)-1.36
EPS (Forward)-5.40
52W Range
2.16092% of range16.00
52W High16.00 USD
52W Low2.160 USD
Profitability
Gross Margin0.00%
Oper. Margin-4119.34%
EBITDA Margin0.00%
Profit Margin-1046.39%
ROE-15.49%
ROA-14.42%
Growth
Revenue Growth0.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.81M USD
CapEx (TTM)—
FCF Margin-2004.41%
FCF Yield-21.80%
Net Debt-46.64M USD
Net Debt/EBITDA1.54
Balance Sheet
Debt/Equity0.00
Current Ratio12.92
Quick Ratio11.30
Book Value/Sh9.504 USD
Cash/Share8.832 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateFeb 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.30M
Float3.16M
Insiders4.15%
Institutions96.07%
Short Interest
Short Ratio23.9d
Short % Float35.77%
Short % Out.29.74%
Shares Short1.57M
Short (prev mo.)1.11M
Technical
SMA 5010.26 (+45.1%)
SMA 2006.564 (+126.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)443.35K
Avg Vol (10d)86.01K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—